BNTC

10.77 +0.47 (+4.56%)

Benitec Biopharma Inc · NASDAQ

Performance

+3.66%

1W

-5.61%

1M

-6.18%

3M

+16.81%

6M

-14.73%

YTD

+277.88%

1Y

Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Technical Analysis of BNTC 2025-01-21

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 36 indicating a weak trend, while the Technical Score of 43 and Oscillators Score of 50 suggest a neutral stance overall. This combination implies caution, as the market lacks strong bullish momentum.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of BNTC

Created with Highcharts 11.1.0212155555514140100
QualityGrowthMomentumValue4

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.